MTOR and breast cancer: Aberrations in phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathways have been investigated in a metastatic breast cancer setting [24,25,26].